Press Releases

Date	Title	Company
10-Nov-2023	Chronic Kidney Disease Treatment Market Sets New Record, Predicted to Hit USD 47.9 Billion by 2032, at 4% CAGR: Claims AMR	The Wire Times
10-Nov-2023	AdaptHealth Corp. to Participate in Upcoming Investor Conferences	Businesswire
10-Nov-2023	ReCode Therapeutics to Participate in November Conferences	Businesswire
10-Nov-2023	Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023	Businesswire
10-Nov-2023	ATCC Products to be Used in Microgravity Experiments on the International Space Station	Businesswire
10-Nov-2023	Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting	Businesswire
10-Nov-2023	Boston Pharmaceuticals Announces Positive Phase 2a Data Supporting Once-monthly Dosing With Investigational BOS-580 in NASH and Treatment Effects in Diabetic Subgroups at AASLD The Liver Meeting® 2023	Businesswire
10-Nov-2023	Immunome to Present at the Stifel 2023 Healthcare Conference	Businesswire
10-Nov-2023	Establishment Labs Announces Participation in Two Upcoming Investment Conferences	Businesswire
10-Nov-2023	Global Electronic Weighing Scales Strategic Analysis Report 2023-2030 with Focus on 135+ Select Players - ResearchAndMarkets.com	Businesswire
10-Nov-2023	NanoSyrinx appoints Anthony Johnson as Non-Executive Director	Businesswire
10-Nov-2023	Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as First-Line Treatment for Locally Advanced Unresectable or Metastatic Biliary Tract Cancer	Businesswire
10-Nov-2023	JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA	Businesswire
10-Nov-2023	JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA	Businesswire
10-Nov-2023	FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma	Businesswire
10-Nov-2023	Imvax to Present New Data on Lead Program, IGV-001, at 2023 SNO Annual Meeting	Businesswire
10-Nov-2023	Positive CHMP opinion received for Blueprint Medicine’s AYVAKYT® (avapritinib)	Blueprint Medicine
10-Nov-2023	IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma	IO Biotech
10-Nov-2023	Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements	Vita 34 AG
10-Nov-2023	Anti-Metabolite Drugs Market to Observe Prominent Development Rate of 7.60% by 2029	The Wire Times